Indian Pharma Industry Trends to Watch in 2026

India's pharma industry is on track to cross the USD 65 billion mark in 2026. Beyond the headline numbers, here are eight trends that will shape what franchise buyers, distributors, manufacturers and clinicians actually see on the ground this year.

1. PCD Franchise Goes Premium

The PCD model is no longer about cheap generics. Premium chronic therapies — cardiac, diabetic, gynaec, derma, neuro — now drive the bulk of franchise margins. Distributors who upgrade their basket are doubling income.

2. Nutraceutical Boom Continues

FSSAI registrations in the nutraceutical category have grown 5x in three years. Collagen, biotin, plant protein and probiotics are crossing over from D2C into chemist counters and clinics — opening new franchise opportunities.

3. WHO-GMP Becomes Table Stakes

Following the Schedule M revisions, WHO-GMP compliance is no longer a "nice to have" — buyers and exporters expect it as a baseline. Franchise companies still operating from non-GMP units will struggle to retain partners.

4. Export Tailwinds for Indian Brands

Africa, CIS, Latin America and Southeast Asia continue to source dossier-ready Indian formulations. Manufacturers with regulatory teams are landing 5-year contracts that subsidise their domestic franchise operations.

5. AYUSH Goes Global

Ayurvedic and herbal brands are seeing unprecedented overseas demand. Standardised herbal extracts, immunity products and stress-management formulations now command 30%+ price premiums in export markets.

6. Hospital Channel Consolidation

Hospital chains are centralising procurement, which means fewer but larger orders. Franchise partners targeting hospitals need to upgrade documentation, GST compliance and credit cycle management.

7. Digital First, Analog Close

Doctors and chemists discover new brands online but still close most franchise deals offline at expos and physical meetings. The winning playbook is digital-first awareness, expo-led closure.

8. Quality Compliance Crackdown

CDSCO and state drug controllers have stepped up inspections after several global recalls. Expect tighter audits, more lab testing and zero tolerance for substandard manufacturing. This is good news for compliant players — bad news for shortcut takers.

What to Do About It

1. Pick partners who already meet WHO-GMP and are compliance-ready.
2. Diversify your basket — add nutraceuticals, derma or ayurvedic to your PCD line.
3. Target chronic and lifestyle therapies for higher margins.
4. Attend at least one major pharma expo per year to stay updated and lock new opportunities.

PharmmaEx 2026 brings together 300+ exhibitors aligned with all of the above trends. Free visitor entry — pre-register today.